Becton Dickinson and Co (BDX) reported fourth-quarter earnings for fiscal 2025, with earnings per share (EPS) of $3.96, matching Wall Street's consensus estimate. Revenue totaled $5.9 billion, slightly below the expected $6.0 billion.
The company's EPS aligns with analyst predictions, reflecting stable operational performance. Becton Dickinson, a global medical technology leader based in Franklin Lakes, New Jersey, specializes in the development and manufacture of medical supplies, devices, and diagnostic products. With a workforce of 74,000 employees, the firm operates through three segments: BD Medical, BD Life Sciences, and BD Interventional, providing a wide range of healthcare solutions.
Becton Dickinson's upcoming earnings are scheduled for August 4, 2026, with EPS and revenue estimates of $3.8338 and $5.8 billion, respectively. This update provides insight into the company's financial health and operational consistency, as it continues to align performance with market forecasts.